TrialAnnals of hematology2025

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

Jens Panse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.